Ha To
Primary Care · Katy, TXNPI 1447794912
Payments from drug & device makers
Across 79 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$392
- Supernus Pharmaceuticals, Inc.$187
- AbbVie$169
- Lilly USA, LLC$162
- AstraZeneca$159
- Sunovion Pharmaceuticals Inc.$121
- plus $571 from 15 others
What the payments were for
- Food & beverage$1,762100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $392 |
| Supernus Pharmaceuticals, Inc. | 6 | $187 |
| AbbVie | 4 | $169 |
| Lilly USA, LLC | 8 | $162 |
| AstraZeneca | 10 | $159 |
| Sunovion Pharmaceuticals Inc. | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $89 |
| Eisai Inc. | 3 | $50 |
| Abbott | 2 | $48 |
| Amarin Pharma, Inc. | 2 | $45 |
| Novartis | 3 | $44 |
| Dexcom, Inc. | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Pfizer | 1 | $22 |
| Boehringer Ingelheim | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Radius Health, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,762 in reported general payments places this provider in the 80th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,425 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort | $159 | $2,42511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 563 primary care providers in Texas.
Other primary care in Katy
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Roxana RoposGrapevine$13K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.